Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.

Title : Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy

Source : CINAHL
ID : 29936654
Authors : Angeles, Arkhjamil; Hung, Wayne; Cheung, Winson Y
Year : 2018
Disease Category : Cancer
Focused Population : Not Specified
Priori/Posteriori : Priori
Single-study Generalibility? : Single
Score/Non-Score : Non-score
Tutorial/Method : Examined treatment attrition rates and eligibility for regorafenib in routine practice
Compared general demographic and patient characteristics : No
Compared disease-specific clinical characteristics : No
Compared adverse events : No
Compared outcomes/treatment effect (including survival) : Yes
Eligible patients (by applying criteria) vs. ineliglble patients (by applying criteria) : Yes
Real-world data sources : British Columbia Cancer Agency diagnosed with mCRC
Target Population Data Type Levels : Regional